RedHill Biopharma (RDHL) Tops Q4 EPS Views

RedHill Biopharma (NASDAQ: RDHL) reported Q4 EPS of $0.06, $0.66 better than the analyst estimate of ($0.60).

EPS in Q413 was 0.05.

For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.

You May Also Be Interested In

• Midday movers: Novavax, Nvidia, Sweetgreen rise; Moderna, Yelp fall
• Membership Collective Group Inc. (SHCO) Tops Q1 EPS by 45c ; Offers Guidance
• Forward Industries (FORD) Reports Q2 Loss of $0.05